At any one time the University of Oxford sponsors around 1,000 academic designed and led clinical research studies within the EU of which about 150 are interventional trials ranging from phase I to phase IV. The University sponsors approximately 350 further studies outside the EU, largely through its Centre for Tropical Medicine and Global Health.
Often in partnership with Oxford University Hospitals Foundation NHS Trust or Oxford Health Foundation NHS Trust most of the EU-based studies are run by one of the University’s six UKCRC fully registered specialist clinical trials units:
- Clinical Trial Service Unit and Epidemiological Studies Unit specializing in major large scale studies and trials of chronic disease;
- Diabetes Trials Unit national and multinational trials of the management and treatment of diabetes;
- Oxford Clinical Trials Research Unit which integrates the following trials groups:
- Centre for Statistics in Medicine
- Critical Care, Trauma and Rehabilitation Trials Group
- Gastroenterology Trials Group
- Oncology Clinical Trials Office (all phases)
- Respiratory Trials Unit
- Surgical Intervention Trials Unit
- NPEU Clinical Trials Unit conducts multicentre trials of a broad range of interventions for women and their families during pregnancy, childbirth, the newborn period and early childhood;
- Primary Care and Vaccines Collaborative Clinical Trials Unit which integrates the Primary Care Trials Unit and the Oxford Vaccine Group
c. 1,000 academic designed and led clinical research studies within the EU
Approximately 350 further studies outside the EU
Clinical Trials News
30 December 2020
The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
17 December 2020
Today, researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.
First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
8 December 2020
Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.